Healthcare Nov 08, 2021 09:55 AM (GMT+8) · EqualOcean
Yiouda health on November 8, following the completion of angel round financing in August, recently, a new generation of assisted reproductive technology innovation company Guangzhou Nuwa Life Technology Co., Ltd. (hereinafter referred to as "Nuwa life") successfully completed Angel round financing. The two rounds of financing were jointly completed by Jue capital investment and Jinsheng capital. Nuwa life is an independent and controllable IVF technology service provider with complete patent authorization, focusing on the R & D and application of assisted reproductive medicine. At present, the company has established a professional team with experience in product development, production, quality control and clinical research. Nuwa life's DNA methylation embryo screening (PIMS) is a new generation of embryo screening technology. Compared with PGs technology, which can only detect chromosome multiples of embryos, PIMS technology can detect chromosome multiples of embryos and DNA methylation status of the whole genome at the same time. After the clinical use of PIMS screening, PGs screening is no longer required. This financing will further promote the industrialization of PIMS.

This text is a result of machine translation.